
Analysts Viewpoint
Deutsche Bank analysts upgrades a Buy rating for Acadia Pharmaceuticals Inc (ACAD)
Acadia Pharmaceuticals Inc’s recently made public that its PRINCIPAL ACCOUNTING OFFICER Kihara James unloaded Company’s shares for reported $90000.0 on